Entrada Therapeutics, Inc.
NASDAQ:TRDA
13.65 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 129.013 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.841 | 1.895 | 1.117 | 0.326 | 0.104 |
| Gross Profit
| 126.172 | -1.895 | -1.117 | -0.326 | -0.104 |
| Gross Profit Ratio
| 0.978 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 97.043 | 66.609 | 35.926 | 21.102 | 8.216 |
| General & Administrative Expenses
| 32.291 | 30.639 | 15.201 | 5.565 | 3.608 |
| Selling & Marketing Expenses
| -0 | 0 | 0 | 0 | 0 |
| SG&A
| 32.291 | 30.639 | 15.201 | 5.565 | 3.608 |
| Other Expenses
| 0 | 0 | 0 | 0 | 6.273 |
| Operating Expenses
| 129.334 | 97.248 | 51.127 | 26.667 | 11.824 |
| Operating Income
| -3.162 | -97.248 | -51.127 | -26.667 | -11.824 |
| Operating Income Ratio
| -0.025 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 15.218 | 2.632 | -0.031 | 0.144 | 6.724 |
| Income Before Tax
| 12.056 | -94.616 | -51.158 | -26.523 | -5.1 |
| Income Before Tax Ratio
| 0.093 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 18.741 | -7.159 | -1.086 | -0.144 | -0.451 |
| Net Income
| -6.685 | -87.457 | -50.072 | -26.379 | -4.649 |
| Net Income Ratio
| -0.052 | 0 | 0 | 0 | 0 |
| EPS
| -0.2 | -2.79 | -1.6 | -0.84 | -0.15 |
| EPS Diluted
| -0.2 | -2.79 | -1.6 | -0.84 | -0.15 |
| EBITDA
| -0.321 | -97.248 | -51.127 | -26.341 | -11.72 |
| EBITDA Ratio
| -0.002 | 0 | 0 | 0 | 0 |